- Latest available (Revised)
- Point in Time (22/07/2016)
- Original (As made)
Point in time view as at 22/07/2016. This version of this provision has been superseded.
You are viewing this legislation item as it stood at a particular point in time. A later version of this or provision, including subsequent changes and effects, supersedes this version.
Note the term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section.
There are currently no known outstanding effects for the The Medicines for Human Use (Clinical Trials) Regulations 2004, Section 3.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
3.—(1) In these Regulations, subject to the following paragraphs, “sponsor” means, in relation to a clinical trial, the person who takes responsibility for the initiation, management and financing (or arranging the financing) of that trial.
(2) If two or more persons take responsibility for the matters specified in paragraph (1) in relation to a clinical trial, those persons may—
(a)take joint responsibility for carrying out the functions of the sponsor of that trial under these Regulations; or
(b)allocate responsibility for carrying out the functions of the sponsor of that trial in accordance with paragraphs (4) to (10).
(3) If two or more persons take joint responsibility in accordance with paragraph (2)(a)—
(a)any reference to the sponsor in these Regulations shall, in relation to that trial, be construed as a reference to those persons; and
(b)paragraphs (4) to (10) shall not apply.
(4) One of the persons referred to in paragraph (2) shall be responsible for carrying out the functions of a sponsor under Part 3 (authorisation for clinical trials and ethics committee opinion) and shall make the request for authorisation to conduct the trial in accordance with regulation 17.
(5) The request for authorisation referred to in regulation 17 shall specify—
(a)who, in accordance with paragraph (4), is responsible for carrying out the functions of the sponsor under Part 3;
(b)who is to be responsible for carrying out the functions of the sponsor under Part 4 (good clinical practice and the conduct of clinical trials); and
(c)who is to be responsible for carrying out the functions of the sponsor under Part 5 (pharmacovigilance).
(6) After the clinical trial has been authorised by the licensing authority in accordance with regulation 18, 19 or 20, a different person may be specified as responsible for carrying out the functions of the sponsor under Part 3, 4 or 5 by making a substantial amendment to the terms of a clinical trial authorisation in accordance with regulations 24 to 26.
(7) Where a person is responsible for carrying out the functions of the sponsor under Part 3 by virtue of paragraph (5), or is specified in accordance with paragraph (6) as responsible for those functions, any reference to the sponsor in—
(a)that Part, except regulation 15,
(b)Parts 2 to 4 of Schedule 3,
(c)Schedule 5, in so far as it relates to decisions of the licensing authority under Part 3, and
(d)Schedule 12,
shall, in relation to the trial, be construed as a reference to that person.
(8) Where a person is specified in accordance with paragraph (5) or (6) as responsible for carrying out the functions of the sponsor under Part 4, any reference to the sponsor in—
(a)that Part, except regulation 28(1), or
(b)Schedule 5, in so far as it relates to notices under regulation 31(1),
shall, in relation to the trial, be construed as a reference to that person.
(9) Where a person is specified in accordance with paragraph (5) or (6) as responsible for carrying out the functions of the sponsor under Part 5, any reference to the sponsor in that Part shall, in relation to the trial, be construed as a reference to that person.
(10) Any reference to the sponsor in—
(a)regulations 15 and 28(1),
(b)Parts 2 and 6 to 9, and
(c)Schedules 1 and 7, and Part 1 of Schedule 3,
shall, in relation to the trial, include a reference to a person specified in accordance with paragraph (5) or (6).
(11) A person who is a sponsor of a clinical trial in accordance with this regulation must—
(a)be established in [F1an EEA State], or
(b)have a legal representative who is so established.
[F2(12) A person who is a sponsor of a clinical trial in accordance with this regulation may delegate any or all of his functions under these Regulations to any person but any such arrangement shall not affect the responsibility of the sponsor.]
Textual Amendments
F1Words in reg. 3(11)(a) substituted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 3(a)
F2Reg. 3(12) inserted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 3(b)
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: